Video

Targeted Therapies in Neuroendocrine Tumors

For High-Definition, Click

The clinical benefits of targeted therapies in neuroendocrine tumors (NETs) have primarily been restricted to the pancreatic type. However, clinical trials are currently under way examining the mTOR inhibitor everolimus in a broader patient population.

The RADIANT-2 trial examined everolimus plus octreotide compared to octreotide and placebo as a treatment for patients with carcinoid tumors, James C. Yao, MD, explains. The hazard ratio for progression-free survival in this trial was 0.77 in favor of treatment with everolimus; however, this benefit was not statistically significant. To further cull out the benefits of everolimus in this population, the RADIANT-4 trial will examine everolimus plus best supportive care compared to supportive care and placebo.

Overall, the efficacy of targeted agents in NETs varies by location with a clear divide appearing between pancreatic NETs and carcinoids. Furthermore, Yao notes, as research continues, a subclassification within carcinoid types may become more apparent. The further subdivision of NETs will be shaped by ongoing trials, Yao believes.

Two important phase III trials in this space, Yao notes, have finished accrual and will help shape further understanding of subclasses. The CLARINET study, Yao notes, is examining lanreotide versus placebo in non-functioning enteropancraetic NETs. Additionally, the SWOG 0518 study is looking at octreotide with interferon alfa-2b compared to octreotide and bevacizumab for advanced, high-risk, NETs.

Related Videos
Kanwal PS Raghav, MBBS, MD
Vikas S. Ostwal, MD
In this episode of OncChats: A Close Look at Clinical Trials in Oncology and Beyond, Dr Carvajal discusses the progress made in cancer clinical trials, with nearly 20,000 trials worldwide and over 80 FDA-approved cancer drugs since 2015, while also noting the challenges posed by the increasing complexity of therapies and trial protocols.
Marcella Ali Kaddoura, MD
Dr Shreenivas on the Association Between MUC1 and CLDN18 in GI Cancers
Dr Strosberg on Cabozantinib vs Placebo in Patients With Advanced GI NETs
Eunice S. Wang, MD
Marcella Ali Kaddoura, MD
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.